SmithKline/Bristol-Myers
Executive Summary
IND for H2 receptor-antagonist BMY 25368, under development by SmithKline, transferred back to Bristol-Myers. The potential "son of Tagamet" was a part of June 1987 swap that involved the granting of U.S. and Canadian comarketing rights to Bristol for OTC cimetidine. SmithKline says it is discussing "the entire situation" with Bristol-Myers....